

ATVB 2012 Scientific Sessions Abstract Submission Information, Instructions, Rules, and Guidelines

Interested investigators are invited to [submit abstracts](#) for presentation at ATVB 2012. Abstracts for the conference will be selected for oral or poster presentation.

The deadline for electronic submission of abstracts is Tuesday, January 10, 2012, 5:00 PM Central Standard Time (CST). To submit your abstract, visit the [conference website](#) . **Please note that you will be charged a processing fee of US \$40 for each abstract you submit.**

Abstracts accepted for presentation at the conference will be published in the online *ATVB* journal after the conference.

Abstract sessions are a forum for the presentation of novel research findings. **Thus, the work covered by the abstract must not have been published (manuscript or abstract) or presented at any national meeting or world congress before April 18, 2012.**

Abstracts may be submitted in the following categories:

- Aortic aneurysm disease
- Apolipoproteins - structure and function
- Blood coagulation and fibrinolysis
- Carotid and peripheral artery disease
- Cellular lipid metabolism
- Clinical aspects of diabetes, obesity and insulin resistance
- Clinical lipidology - diagnostics and therapeutics
- Diabetes, obesity and metabolic disorders
- Immunity and inflammation in vascular biology and atherosclerosis
- Lipoprotein metabolism and therapeutic targets
- Mechanisms of atherosclerosis
- Molecular and cellular biology of the vessel wall
- Platelet production, signaling, and function
- Vascular cells, inflammation, and thrombosis
- Vascular development, differentiation, regeneration and angiogenesis
- Venous thromboembolism: mechanisms, biomarkers and therapy

Rules for Preparation and Submission of Abstracts

The presenting author of an accepted abstract must pay the registration fee to attend ATVB 2012. AHA members save up to \$300 registration discount. You must become a member by Mar. 6, 2012, to receive the reduced registration fee.

All other expenses, (airfare, lodging, etc.) association with the submission and presentation of an abstract are the responsibility of the presenter.

ATVB 2012 is a forum for the presentation of novel research findings. The work covered by the abstract must not have been published before the date and time of presentation (Apr. 18-20, 2012).

Exception: if early career investigators feel compelled to increase their opportunity of scientific interaction, then the abstract submission must have incremental information from the abstract submitted elsewhere to justify submission and presentation at the AHA, should the investigator's work be accepted at both meetings. Each investigator will determine, in good conscience, what constitutes incremental information and should notify AHA staff.

Submission of an abstract constitutes a commitment by the author(s) to present it if accepted. Failure to present, if not justified, will jeopardize future acceptance of abstracts for the American Heart Association.

There is no limit to the number of abstracts an investigator may submit. If selected, the presenter must be one of the co-authors listed.

Embargo Policy

Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA news event. Written embargoed information cannot be shared with anyone but one-on-one embargoed media interviews can be conducted as long as the reporter agrees to abide by the embargo policy. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. Click [here](#) to view the complete AHA/ASA General Embargo Policies

Abstract Title

An abstract must have a short, specific title (containing no abbreviations) that indicates the nature of the investigation.

Author Name(s)

The submitting author is designated as the primary/presenting author. You may rearrange the order of the authors; however, always list the senior author last.

If an author's name appears on more than one abstract, it must be identical on each abstract.

Additions or deletions of author names are not permitted after Feb. 14, 2012, 5:00 PM CDT.

Abstract Data

Describe briefly the objectives of the study unless they are contained in the title. Include a brief statement of methods if pertinent. State findings in detail sufficient to support conclusions. Abstracts should not describe research in which the chemical identity or source of the reagent is proprietary or cannot be revealed.

Do not re-enter the abstract title or the authors' names/institutions.

Use generic drug names.

Authors should not "split" data to create several abstracts from one. If splitting is judged to have occurred, priority scores of related abstracts will be reduced.

Standard abbreviations may be used without definition. Nonstandard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.

Do not include references, credits, or grant support.

Do not include names or personal information of any patient participating in the study or trial.

Abstracts are limited to 1950 characters (about 300-350 words). This includes the text plus any graphic, but not the title or authors. Addition of a graphic will deduct 500 characters. Spaces do not count as characters.

Request oral or poster preferred presentation on the Presentation Preference page of the Abstract System. Selecting oral or poster preferred will neither prejudice acceptance nor guarantee oral or poster presentation, because abstracts must be arranged to fit into a thematic group for presentation. However, the AHA will make every effort to accommodate your presentation request.

If you select "Poster Only" and your abstract is accepted, this request will be granted.

Abstract Revisions

Proofread abstracts carefully to avoid errors. Abstracts may not be revised after **Jan. 5, 2012**.

Abstract Withdrawal

Submit abstract withdrawal requests in writing by February 24, 2012.

Abstract Acceptance

Abstract grading is blinded and abstracts are selected on the basis of scientific merit and are allocated to oral or poster presentations.

Notification of abstract acceptance status will be emailed to presenting authors in February 2012. Please ensure that the email provided is accurate as all correspondences will be sent via email

Accepted abstracts will be published in the online *ATVB* journal after the conference.

Abstract Presentation

Guidelines for presentations will be provided to authors of accepted abstracts.

All presentations and question-and-answer sessions will be conducted in English. Presenters may request assistance from the moderator, who will repeat or rephrase questions from the audience or may ask a colleague in the audience to assist with translation.

No person may record any portion of the *ATVB* 2012 Scientific Sessions, whether by video, still or digital photography; audio; or any other recording or reproduction mechanism. This includes recording of presentations and supporting audiovisual materials and of poster presentations and supporting poster materials.

Additionally, science information shared by investigators at the time of a meeting is confidential and often unpublished data. Taking photos of or recording the content of meeting room slides is also prohibited, and is considered intellectual piracy and unethical. Attendees who ignore this policy will be asked to leave the educational session and are at risk of losing their badge credentials.

The AHA reserves the right to all video or audio recordings of presentations at *ATVB* 2012.

All oral presentations must be in electronic format and submitted at least 3 hours in advance of the session start time. Instructions for presentation upload will be provided upon acceptance.